
Cell Reports

A p300 and SIRT1 Regulated Acetylation Switch of C/EBP α Controls Mitochondrial Function

Graphical Abstract



Authors

Mohamad A. Zaini, Christine Müller, Tristan V. de Jong, ..., Oliver H. Krämer, Victor Guryev, Cornelis F. Calkhoven

Correspondence

c.f.calkhoven@umcg.nl

In Brief

Zaini et al. show that the transcription factor C/EBPa is acetylated by p300 and deacetylated by the lysine deacetylase SIRT1. Hypoacetylated C/EBPa induces the transcription of mitochondrial genes and results in increased mitochondrial respiration. C/EBPa is a key mediator of SIRT1-controlled adaption of energy homeostasis to changes in nutrient supply.

Highlights

- p300 acetylates C/EBPα on several lysines
- SIRT1 deacetylates C/EBPa
- Hypoacetylated C/EBPa increases mitochondrial function
- C/EBPα is a mediator of SIRT1-controlled energy homeostasis

Data and Software Availability E-MTAB-6323





A p300 and SIRT1 Regulated Acetylation Switch of C/EBPα Controls Mitochondrial Function

Mohamad A. Zaini,^{1,2} Christine Müller,¹ Tristan V. de Jong,¹ Tobias Ackermann,¹ Götz Hartleben,¹ Gertrud Kortman,¹ Karl-Heinz Gührs,² Fabrizia Fusetti,³ Oliver H. Krämer,⁴ Victor Guryev,¹ and Cornelis F. Calkhoven^{1,5,*}

¹European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen, University of Groningen, 9700 AD Groningen, the Netherlands

²Leibniz Institute on Aging, Fritz Lipmann Institute, 07745 Jena, Germany

³Department of Biochemistry, Netherlands Proteomics Centre, Groningen Biological Sciences and Biotechnology Institute, University of Groningen, 9747 AG Groningen, the Netherlands

⁴Institute of Toxicology, University Medical Center Mainz, 55131 Mainz, Germany ⁵Lead Contact

*Correspondence: c.f.calkhoven@umcg.nl

https://doi.org/10.1016/j.celrep.2017.12.061

SUMMARY

Cellular metabolism is a tightly controlled process in which the cell adapts fluxes through metabolic pathways in response to changes in nutrient supply. Among the transcription factors that regulate gene expression and thereby cause changes in cellular metabolism is the basic leucine-zipper (bZIP) transcription factor CCAAT/enhancer-binding protein alpha (C/EBP α). Protein lysine acetylation is a key post-translational modification (PTM) that integrates cellular metabolic cues with other physiological processes. Here, we show that C/EBP α is acetylated by the lysine acetyl transferase (KAT) p300 and deacetylated by the lysine deacetylase (KDAC) sirtuin1 (SIRT1). SIRT1 is activated in times of energy demand by high levels of nicotinamide adenine dinucleotide (NAD⁺) and controls mitochondrial biogenesis and function. A hypoacetylated mutant of C/EBPa induces the transcription of mitochondrial genes and results in increased mitochondrial respiration. Our study identifies C/EBP α as a key mediator of SIRT1-controlled adaption of energy homeostasis to changes in nutrient supply.

INTRODUCTION

Studies in cell culture and with mouse models have demonstrated a key role for CCAAT/enhancer-binding protein alpha (C/EBP α) in regulating the transcription of metabolic genes. C/EBP α deficiency in mice results in severe metabolic phenotypes, particularly affecting the liver tissue structure and its functions in gluconeogenesis, glycogen synthesis, and bilirubin clearance, and its deficiency affects fat storage in white adipose tissue (WAT) (Wang et al., 1995; Darlington et al., 1995; Croniger et al., 1997; Inoue et al., 2004; Lee et al., 1997; Yang et al., 2005). In addition, C/EBP α and peroxisome proliferator-activated receptor gamma (PPAR γ) are key factors in the transcriptional network controlling adipocyte differentiation (Lefterova et al., 2008; Rosen et al., 2002; Siersbæk and Mandrup, 2011), and mutations of phosphorylation sites in regulatory domains of C/EBP α result in dysregulated transcription of genes involved in glucose and lipid metabolism *in vivo* (Pedersen et al., 2007; Lefterova et al., 2008). Hence, C/EBP α is a key factor for the differentiation and function of hepatocytes and adipocytes and plays an essential role in the regulation of energy homeostasis.

Protein lysine acetylation is a key post-translational modification (PTM) that integrates cellular metabolic cues with other physiological processes, including cell growth and proliferation, circadian rhythm, and energy homeostasis (Menzies et al., 2016; Choudhary et al., 2014; Xiong and Guan, 2012). Acetylation may regulate various functions of the acetylated proteins, including changes in DNA binding, protein stability, enzymatic activity, protein-protein interactions, and subcellular localization. Protein acetylation is a reversible process in which an acetyl group is transferred from an acetyl coenzyme A (acetyl-CoA) to the target lysine residue by lysine acetyl transferases (KATs) and is removed by lysine deacetylases (KDACs). The KATs and KDACs consist of a large group of enzymes originally identified to acetylate histones as part of epigenetic mechanisms. Later also non-histone proteins were identified as KAT targets (Menzies et al., 2016). Sirtuins (class III KDACs) are KDACs that require nicotinamide adenine dinucleotide (NAD⁺) as co-factor for their enzymatic activity and therefore are activated in times of energy demand when NAD⁺ levels are high (high NAD⁺/ NADH ratio) (Houtkooper et al., 2012).

Involvement of KATs in C/EBP α -mediated transcription has been reported in the past (Bararia et al., 2008; Erickson et al., 2001; Jurado et al., 2002; Yoshida et al., 2006), but the role C/EBP α protein lysine acetylation in the transcriptional regulation of metabolic genes has not been addressed. Because C/EBP α is a key regulator of metabolism, we hypothesized that reversible acetylation of C/EBP α is decisively involved in regulating metabolic homeostasis. Here we show that C/EBP α is acetylated on lysines K159 and K298 by the KAT p300, which modulates the transcriptional activity of C/EBP α . We show that acetylation of C/EBP α is dependent on glucose availability, and we identify sirtuin1 (SIRT1) as the sole sirtuin that mediates NAD⁺-dependent deacetylation of C/EBP α . A hypoacetylated mutant of C/EBP α induces the expression of genes involved in




Figure 1. Acetylation of C/EBPa by p300 Enhances Its Transactivation Activity

(A) Immunoblot analysis of immunoprecipitated (IP) C/EBP α and total lysates (Input) of Fao cells cultured overnight in either high-glucose (25 mM) or low-glucose (5 mM) medium. Antibody staining as indicated.

(B) Immunoblot analysis of immunoprecipitated (IP) C/EBPa and total lysates (Input) of HEK293T cells ectopically expressing C/EBPa or empty vector (E.V.) control. Antibody staining as indicated.

(C) HEK293T cells were transiently transfected with C/EBP-responsive firefly reporter vector, a *Renilla* expression vector for normalization, C/EBP α , and/or one of the lysines acetyl transferases (KATs) expressing vector as indicated. Luciferase activity was measured 48 hr later (n = 4).

(D) HEK293T cells were transiently transfected with luciferase C/EBP-responsive firefly reporter vector, *Renilla* expression vector for normalization, C/EBP α , and increased amounts of either WT p300-HA or Δ KATp300-HA (p300 with its lysine acetyl transferase domain deleted) expression vectors. Luciferase activity was measured 48 hr later (n = 4).

(E) Immunoblot analysis of HA-immunoprecipitated (IP) p300-HA and total lysates (Input) of HEK293T cells ectopically expressing C/EBP α and p300-HA or empty vector (E.V.) control. Antibody staining as indicated.

the function of the mitochondrion and oxidation-reduction processes, which is accompanied by an increase in mitochondrial mass and cellular oxygen consumption rates. Our study shows that reversible acetylation of C/EBP α in response to changed metabolic conditions alters its transcriptional function to adapt metabolic gene expression and plays an important role in SIRT1-controlled cellular metabolic homeostasis.

RESULTS

Acetylation of C/EBPα by p300 Enhances Its Transactivation Activity

The presence of 15 conserved lysines in sequences of vertebrate C/EBP α orthologs suggests that C/EBP α is a potential target for lysine acetylation (Figure S1). Glucose-rich cell culture conditions are known to increase protein-acetylation through increased availability of acetyl-CoA as substrate for KATs to donate an acyl group to the target lysine (Shi and Tu, 2015). Acetylation of endogenous C/EBP α in lysates from the Fao rat hepatoma cell line was detected using an anti-acetylated lysine (anti-Ac-K) antibody following immunoprecipitation (IP) of C/EBP $\!\alpha$ under high-glucose (25 mM) conditions, which was reduced under low-glucose (5 mM) conditions (Figure 1A). Acetylation of immunoprecipitated C/EBPa was also detected in HEK293T cells lacking endogenous C/EBPa that were transfected with a C/EBP α expression vector (Figure 1B). Next we investigated whether co-expression of the four major KATs, p300, P/CAF, GCN5, and Tip60, alters the transcriptional activity of C/EBPa using a luciferase-based reporter solely containing two natural C/EBP-binding sites of the cMGF promoter (Sterneck et al., 1992). Co-transfection with p300 resulted in an increase in C/EBPa-induced promoter activity in a dose-dependent manner, whereas co-transfection with the other KATs had no significant effect (Figures 1C, 1D, and S2A). To investigate a direct interaction between C/EBP α and p300 as well as three additional major KATs, we co-expressed C/EBP α with p300-HA, P/CAF-FLAG, GCN5-FLAG, or Tip60 in HEK293T cells and performed coimmunoprecipitation (coIP) experiments using anti-C/EBP α antibodies. C/EBP α co-precipitated with p300, P/CAF, and GCN5, but not Tip60 (Figure S2B), which was confirmed by reciprocal coIP of the C/EBP α with the same KATs (Figures 1E and S2C). To examine whether the intrinsic KAT function of p300 is involved in C/EBPa acetylation and transactivation potential, we co-expressed C/EBP α with either p300 or p300 with its KAT domain deleted (p300∆KAT-HA) and analyzed C/EBPa acetylation and p300 binding by C/EBPa coIP. C/EBPa acetylation was abolished by expression of p300∆KAT-HA (Figure 1F). In addition, the p300-dependent C/EBPa transactivation activity is abrogated by deletion of the p300-KAT (Figure 1D). In addition, p300-mediated acetylation of C/EBP α in HEK293 cells is strongly reduced under lowglucose conditions (5 mM), confirming that protein acetylation is facilitated under conditions of high acetyl-CoA availability (Figure 1G). Moreover, in Fao cells, acetylation of endogenous C/EBP α was abolished by treatment with the p300 inhibitor C646 (Figure 1H). Therefore, we propose that p300 catalyzes the acetylation of C/EBP α and thereby alters its transcriptional function.

Lysine (K) 298 of C/EBPa was recently identified as an acetylation site using the anti-Ac-K298-C/EBPa antibody (Bararia et al., 2016). Using this antibody, a co-expression experiment with p300 in HEK293T cells showed that K298 of C/EBP α is also acetylated by p300 (Figure S2D). In addition, both the endogenously expressed C/EBPa isoforms p42 and p30 (Calkhoven et al., 2000) in Fao cells are acetylated at K298, which is dependent on high-glucose conditions (Figure S2E). Changes in nutrient and calorie intake can influence acetylation of regulatory proteins through changes in cellular concentrations of acetyl-CoA and NAD⁺ (Houtkooper et al., 2012; Verdin and Ott, 2015). To examine C/EBP α acetylation under different metabolic conditions in vivo, we analyzed livers from mice that were subjected to either calorie restriction (CR; 4 weeks) or a high-fat diet (HFD; 20 weeks). By using anti-Ac-K298-C/EBPa, we found a decrease in C/EBP α K298-acetylation in livers of CR mice and an increase of its acetylation in livers of HFD mice (Figures S2F and S2G; shown is the p30-C/EBPa). Taken together, our data show that C/EBPa acetylation changes with nutritional status in vivo.

The IP experiments described above do not reveal to what extent or which of the lysines in C/EBP α are acetylated by p300 beyond K298. To examine the distribution of lysine acetylation, we purified acetylated C/EBP α protein derived from HEK293T cells co-expressing C/EBP α and p300 and examined protein acetylation by mass spectrometric analysis (Figure 2). Of the 15 lysines in C/EBP α , 11 were covered by the analyzed peptides, of which 5 (K159, K250, K273, K275, and K276) were found acetylated and 6 (K92, K169, K280, K304, K313, and K352) not acetylated (Figure 2). Taken together, our analyses suggest that C/EBP α is subject to extensive acetylation mediated by p300 and that acetylation enhances its transactivation activity.

C/EBPa Binds to and Is Deacetylated by SIRT1

Lysine acetylation is a reversible PTM, which implies that specific KDACs may be responsible for C/EBP α deacetylation. The dependence of C/EBP α acetylation on glucose (Figures 1A and 1G) and the fact that C/EBP α and sirtuins both regulate glucose and fatty acid metabolism suggested that the NAD⁺dependent sirtuin deacetylases (SIRTs) could be involved. We examined the potential involvement of the four cytoplasmic

⁽F) Immunoblot analysis of immunoprecipitated (IP) C/EBP α and total lysates (Input) of HEK293T cells ectopically expressing C/EBP α and p300-HA or Δ KATp300-HA. Antibody staining as indicated.

⁽G) Immunoblot analysis of immunoprecipitated (IP) C/EBPα and total lysates (Input) of HEK293T cells ectopically expressing C/EBPα and p300-HA or empty vector (E.V.) control and cultured overnight in either high-glucose (25 mM) or low-glucose (5 mM) medium. Antibody staining as indicated.

⁽H) Immunoblot analysis of immunoprecipitated (IP) C/EBPα and total lysates (Input) of Fao cells treated overnight with either DMSO or p300 inhibitor (C646, 10 μM). Antibody staining as indicated.

Statistical differences were analyzed using Student's t tests. Error bars represent ± SD. ***p < 0. 001; NS, not significant.

Peptide sequence		Mascot score	Position				
PLVIKQEPR		59	K159				
GPGGSL <mark>K</mark> GLAGPHPPDLR		54	K250				
TGGGGGGGGAGAG <mark>KAKK</mark> SVVDK		50	K273/K275/K276				
				-			
K - acetylated K - not acetylated					K276 K275	K304 K302	
K - not covered	K90 K9	2 K	(159 K169			K298 K313 K32	3 K352
	TAD1		TAD2	AD3	DBD	D LZIP	
1							358

Figure 2. C/EBP α Is Acetylated by p300 at Multiple Lysines

MS analyses identify the C/EBP α acetylation sites in HEK293T cells transfected with expression plasmids for C/EBP α and p300-HA. Mascot scores (top) >40 were most confident for the true detection of acetylation. The lower graph represents the C/EBP α protein with the acetylation status of its 15 lysines and locations of the transactivation domains (TADs), DNA-binding domain (DBD), and leucine-zipper dimerization domain (LZIP).

and nuclear sirtuins, SIRT1, SIRT2, SIRT6, and SIRT7, as well as SIRT3, which is mainly mitochondrial but may have nuclear functions in addition (Houtkooper et al., 2012). The mitochondrial SIRT4 and SIRT5, which can act in both the mitochondria and cytosol (Nishida et al., 2015; Park et al., 2013), were not tested. To examine possible C/EBPa-sirtuin interactions, C/EBPa was co-expressed together with one of the FLAGtagged sirtuins in HEK293T cells. CoIP using an anti-C/EBPa antibody followed by immunoblotting with an anti-FLAG antibody revealed that only SIRT1 interacts with C/EBPa (Figure 3A). The interaction between C/EBPa and SIRT1 was confirmed by reciprocal coIP using an anti-FLAG antibody (Figure 3B). Next we examined the capacity of SIRT1 to deacetylate C/EBPa. HEK293T cells were co-transfected by C/EBPa and p300 expression plasmids to obtain acetylated C/EBPa in the presence of either SIRT1 or SIRT2 expression plasmids or empty vector control. Following C/EBPa IP, immunoblotting with an anti-HA or anti-Ac-K antibody showed binding to p300 and a high level of C/EBPa acetylation, respectively, which are abrogated by co-expression of SIRT1 (Figure 3C). Co-expression of SIRT2, which does not interact with C/EBPa, has no effect on C/EBP α acetylation (Figure 3C). In addition, the ASEB computer algorithm (http://bioinfo.bjmu.edu.cn/huac/; Wang et al., 2012) for prediction of SIRT1-mediated deacetylation lists all the mass spectrometry-identified lysines and K298 as potential SIRT1 deacetylation sites (Table S1). Furthermore, a progressive increase in expression levels of SIRT1 resulted in a progressive decrease in the acetylation level of C/EBPa (Figure 3D), which is accompanied by a progressive decrease in p300-dependent C/EBPα transactivation potential (Figure 3E). To examine whether C/EBPa deacetylation by SIRT1 is attributed to the enzymatic activity of SIRT1, we set up an in vitro deacetylation assay. Purified FLAG-tagged acetylated C/EBPa was obtained by anti-FLAG-IP from HEK293T cells that were co-transfected with C/EBPa-FLAG and p300 expression plasmids. Purified FLAG-tagged SIRT1 was obtained separately by anti-FLAG-IP from HEK293T cells transfected with a SIRT1-FLAG expression plasmid. The deacetylation reaction assay revealed that SIRT1 efficiently deacetylates C/EBP α in the presence of NAD⁺ in vitro (Figure 3F). Moreover, the deacetylation of C/EBPa by SIRT1 was inhibited in the presence of the sirtuin inhibitor nicotinamide (NAM). Taken together, our data show that lysine residues in C/EBPa can be deacetylated by SIRT1.

Acetylation of C/EBP α Does Not Alter Its Subcellular Localization or DNA Binding

Lysine acetylation of a transcription factor may serve to alter its transcriptional function, its DNA-binding properties, or its subcellular localization (Choudhary et al., 2014). We first examined whether the presence of either p300 or SIRT1 alters the subcellular localization of C/EBPa. Immunofluorescent staining of C/EBPa in HEK293T cells showed no difference in its nuclear localization between hyperacetylated C/EBPa derived from cells co-expressing p300 or hypoacetylated C/EBPa derived from cells co-expressing SIRT1 (Figures 4A and S3A). To determine whether co-expression of p300 or SIRT1 alters the binding of C/EBPa to a DNA recognition sequence, purified (IP) FLAGtagged C/EBPa wild-type (WT) was incubated with DNA oligonucleotide probes of either a C/EBP-consensus sequence or a mutated sequence, and DNA-protein complexes were analyzed in an electrophoretic mobility shift analysis (EMSA). SYBR Green DNA and SYPRO Ruby protein staining revealed that there is no difference in the DNA binding of C/EBPa between cells co-expressing p300 or co-expressing SIRT1 (Figure 4B). No DNA binding was detected with the C/EBPa-mutated binding sites. These data show that acetvlation status of C/EBPa does not affect DNA binding in a significant way.

To examine the involvement of acetylation of individual C/EBP α lysines on the transactivation activity of C/EBP α , we generated mutations that mimic either acetylation (lysine [K] to glutamine [Q]) or non-acetylation (lysine [K] to arginine [R]) at the acetylated lysines identified by mass spectrometry, K159, K250, K273, K275, and K276, and the established acetylation site, K298. Figure 4C shows that only the single K159Q or K298Q acetylation-mimicking mutations in C/EBP α result in enhanced C/EBP α transactivation capacity compared with the WT C/EBP α , using the C/EBP-binding site reporter. None of the K-to-R acetylation-preventing mutations altered the reporter activity (Figure 4D).

Next we examined subcellular localization of the dual K159Q/ K298Q acetylation-mimicking and K159R/K298R non-acetylation mutants of C/EBP α . Neither mutation affected the subcellular localization (Figure 4E). In addition, the mutations do not affect DNA binding in an EMSA (Figure 4F). Furthermore, binding to the C/EBP-binding site in the reporter was not altered by the lysine mutations as was measured by C/EBP α IP and qRT-PCR quantification of bound DNA (Figures 4G and S2B). Finally, chromatin IP (ChIP) experiments showed that there is no




Figure 3. C/EBPa Binds to and Is Deacetylated by SIRT1

(A) Immunoblot analysis of immunoprecipitated (IP) C/EBPa and total lysates (Input) of HEK293T cells ectopically expressing C/EBPa and one of the FLAGtagged sirtuins. Antibody staining as indicated.

(B) Immunoblot analysis of FLAG-immunoprecipitated (IP) SIRT1 and total lysates (Input) of HEK293T cells ectopically expressing C/EBP α and SIRT1-FLAG or empty vector (E.V.) control. Antibody staining as indicated.

(C) Immunoblot analysis of immunoprecipitated (IP) C/EBPa and total lysates (Input) of HEK293T cells ectopically expressing C/EBPa and p300-HA, and SIRT1-FLAG or SIRT2-FLAG. Antibody staining as indicated.

(D) Immunoblot analysis of immunoprecipitated (IP) C/EBPa and total lysates (Input) of HEK293T cells ectopically expressing C/EBPa and p300-HA and increased amounts of SIRT1-FLAG. Antibody staining as indicated.

(legend continued on next page)

difference in binding between WT C/EBP α , the K159Q/K298Q C/EBP α mutant, or K159R/K298R C/EBP α mutant to natural C/EBP-binding sites in promoters of the endogenous genes G-CSFR and PEPCK1 (Figures 4H and S3B). Therefore we conclude that acetylation of the lysines K159/K298 enhanced C/EBP α transactivation without affecting subcellular localization or DNA binding.

Acetylation of Lysine 298 of C/EBPa Stimulates Acetylation of Subsequent Lysines

Next we asked whether prevention of acetylation of K159, K298, or all six lysines by K-to-R mutations affects p300 binding and acetylation or the transactivation potential of C/EBPa. K-to-R mutated C/EBPa mutants were co-expressed with p300 in HEK293T cells, and p300 binding and C/EBPa acetylation were analyzed after C/EBPa IP. Notably, the mutation K298R strongly reduced binding to p300, associated with a strong reduction in C/EBPα acetylation (Figure 5A). The K159R single mutation had no effect on p300 binding and C/EBPa acetylation, although in the double mutant K159/298R, the level of C/EBPa acetylation was further decreased (Figure 5A). As expected, mutation of all six lysines (K159, K250, K273, K275, K276, and K298) in the K6R mutant reduced C/EBPa acetylation by p300 to very low levels. In accordance, the transactivation of the C/EBP reporter is similar for co-expression of WT or K159R-C/EBPa, decreased for K298R-C/EBPa, and further decreased for K159/298R- and K6R-C/EBPα (Figure 5B). Complementary results were obtained with the opposite lysine acetylation-mimicking K-to-Q mutations. The K159Q mutant did not significantly improve binding of C/EBPa to p300 or C/EBPa acetylation, while with the K298Q mutant, p300 binding and C/EBPa acetylation were strongly increased, and there was a further increase for the double mutant K159/298Q (Figure 5C). The K6Q mutation also results in enhanced binding of p300 and a stronger acetylation signal, although the anti-L-Ac antibody does not recognize the KQ mutations. This suggests that in the K6Q mutant, acetvlation of other lysines increases, which normally are not efficiently acetylated. Co-expression of the K-to-Q C/EBPa mutants, p300, and the luciferase C/EBP reporter resulted in a gradual increase in reporter activity from K159Q- to K298Q- to K159/298Q- and K6Q- C/EBPα (Figure 5D). Finally, increasing amounts of SIRT1 co-expression did not reduce the transactivation potential through deacetylation of either K159/298Q- or K6Q-C/EBPα (Figure S4). Together, these results suggest that K298 acetylation is a priming acetylation event stimulating the recruitment of p300, acetylation of K159, and further acetylation of C/EBPa.

C/EBPα Acetylation Status Determines the C/EBPα-Regulated Transcriptome

To investigate the consequences of C/EBP α acetylation on global C/EBP α -controlled gene transcription, we generated


Hepa1-6 mouse hepatoma cell lines with cumate-inducible expression of WT, K159Q/K298Q-, or K159R/K298R-C/EBPa-FLAG proteins (Figure 6A). Comparative transcriptome analysis identified 110 upregulated transcripts and 122 downregulated transcripts in the hypoacetylation K159R/K298R-C/EBPa mutant versus hyperacetylation K159Q/K298Q-C/EBPa mutant expressing cells (Figure 6B). We considered genes to be differentially regulated between the hypo- and hyperacetylation C/EBPa mutants only if their expression levels were intermediate in the WT C/EBPa-expressing cells. Ten of each up- or downregulation genes were re-analyzed by qRT-PCR, confirming their regulation shown by the transcriptome analysis (Figure 6C). Gene Ontology (GO) analysis using the DAVID database (Huang et al., 2009) revealed that the upregulated transcripts in the K159R/K298R-C/EBPa mutant-expressing cells are enriched for genes in oxidation-reduction processes and mitochondrial biology, while the downregulated transcripts are enriched for glycoprotein genes (Figure 6D; Table S2). Most of the regulated genes have C/EBPβ-associated DNA fragments in the ENCODE database (http://genome.ucsc.edu/ENCODE/; Table S2). C/EBP β is closely related to C/EBP α , and because they bind to the same recognition sequences, C/EBPß may substitute for C/EBPa, for which data are not available. In the metabolic context, these results suggest that deacetylation of C/EBPa is involved in the SIRT1-controlled increase in mitochondrial biogenesis and function under conditions of low glucose and low energy.

Hypoacetylated C/EBP α Enhances Mitochondrial Function

In line with a role of hypoacetylated C/EBPa in mitochondrial regulation, we found that cumate induction of the K159R/ K298R-C/EBP α mutant in Hepa1–6 cells that are cultured in acetylation-favoring high-glucose medium results in increased accumulation of MitoTracker fluorescent dye as a measure for mitochondrial mass, compared with the hyperacetylation K159Q/K298Q- or WT C/EBPa (Figures 7A and S5A). In addition, under low-glucose deacetylation-favoring conditions (2.5 mM), WT reaches similar mitochondrial mass compared with hypoacetylation K159R/K298R-C/EBPa, while the acetylationmimicking K159Q/K298Q-C/EBPa fails to increase mitochondrial mass (Figure 7A). The relative mtDNA copy number did not change upon expression of the C/EBP α variants (Figure S5B). To examine whether C/EBPa is required for SIRT1-dependent induction of mitochondrial mass, we stimulated SIRT1 activity by treatment with SIRT1 activator II and compared mitochondrial mass of cells with short hairpin C/EBPa (sh-C/EBPa) knockdown to control short hairpin RNA (shRNA). Treatment with SIRT1 activator II resulted in a clear increase in mitochondrial mass in control cells that was almost completely abrogated in C/EBPaknockdown cells (Figure 7B). Taken together, these data show

⁽E) HEK293T cells transfected with luciferase C/EBP α responsive promoter vector, *Renilla* expression vector for normalization, C/EBP α , p300-HA, and increased amounts of SIRT1 expression vectors as indicated. Luciferase activity was measured 48 hr later (n = 3). Statistical differences were analyzed using Student's t tests. Error bars represent ±SD. *p < 0.05, ***p < 0.001; NS, not significant.

⁽F) In vitro SIRT1 deacetylation assay for C/EBP α . C/EBP α -FLAG and SIRT1-FLAG proteins were purified from HEK293 cells by IP with anti-FLAG M2 beads. The indicated proteins were incubated at 30°C for 1 hr with NAD⁺ or NAM as indicated, followed by immunoblotting with anti-acetylated lysine, anti-C/EBP α , and anti-FLAG antibodies.



(legend on next page)

that deacetylation of C/EBP α is required for the SIRT1-induced increase in mitochondrial mass.

To investigate whether mitochondrial function is affected by C/EBP α acetylation, we measured using the Seahorse XF extracellular flux analyzer basal oxygen consumption rate (OCR), maximal OCR (treatment with mitochondrial uncoupler 2,4-dinitrophenol [DNP]), and spare respiratory capacity (SRC) as indicators of mitochondrial respiration. In addition, we measured extracellular acidification rate (ECAR) and maximal ECAR (treatment with oligomycin) as measurement of glycolysis. Under high-glucose (25 mM) acetylation-favoring conditions, expression of the hypoacetylation K159/298R-C/EBP α mutant results in an increases in basal OCR, maximal OCR, and SRC (Figures 7C and S5C). This indicates that the hypoacetylated C/EBP α induces mitochondrial respiration. In addition, the hypoacetylation K159/298R-C/EBP α mutant increases basal and maximal ECAR (Figures 7D and S5D).

Under low-glucose (2.5 mM) deacetylation-favoring conditions, expression of WT C/EBPa increased mitochondrial respiration (basal OCR, maximal OCR, and SRC) to similar extents as the hypoacetylation K159/298R-C/EBPa mutant. Expression of the hyperacetylation K159/298Q-C/EBPa mutant did not result in a comparable increase in respiration (Figures 7E and S5E). Induction of the hypoacetylation K159/298R-C/EBPa did not increase ECAR compared with WT C/EBPa, while the K159/ 298Q-C/EBPa mutant mildly decreased the maximal ECAR (Figures 7F and S5F). These data indicate that induction of respiration by C/EBPa requires its lysine residues either to be available for deacetylation or being mutated to mimic hypoacetylation. To test whether SIRT1 activation is required for the induction of respiration by WT C/EBPa under low-glucose conditions, the cells were treated with the SIRT1 inhibitor Ex-527 (selisistat), which completely inhibited the WT C/EBPa-induced basal OCR, maximal OCR, and SRC under the low-glucose (2.5 mM) deacetylation-favoring condition (Figures 7G and S5G).

Taken together, our data suggest that deacetylation of C/EBP α is part of the SIRT1-controlled increase in mitochondrial biogenesis and function.

DISCUSSION

In this study, we demonstrate that C/EBP α is acetylated by p300 and deacetylated by SIRT1 and that the acetylation status of C/EBPa determines its transcriptional functions. By using acetylation-mimicking (KQ) or acetylation-preventing (KR) mutations, our data suggest that acetylation of lysine residue K298 primes for p300-catalyzed acetylation at various additional lysines and that the K159/298Q dual mutation can substitute for maximal acetylation levels. We show that the acetylation status of C/EBPa modified by p300, SIRT1, and K159/298Q mutations or by K159/298R mutations does not alter its cellular localization or DNA binding. Whole coding transcriptome analysis revealed that the hypoacetylation K159/298R-C/EBPα mutant induces transcripts involved in mitochondrial function and oxidationreduction processes. Accordingly, expression of K159/298R-C/EBPa increases mitochondrial mass and respiration whereas C/EBPa knockdown abrogates the increase in mitochondrial mass induced by SIRT1 activation. Furthermore, inhibition of SIRT1 blunts WT C/EBPa-induced mitochondrial respiration under low-glucose conditions. Our data fit into a model in which C/EBPa functions downstream of SIRT1 to transcriptionally adapt mitochondrial function in response to alterations in the cellular energy and nutrition state. The more subtle increase in ECAR upon K159/298R-C/EBPa induction, suggesting an increase in glycolysis, is observed only under high-glucose conditions. Possibly, the higher metabolic (respiration) rate of the K159/298R-C/EBPa-expressing cells allows more glucose uptake under high-glucose conditions that is constrained by lowglucose availability.

The results of the transcriptome analysis, revealing differential up- or downregulation of distinct endogenous genes by the hypoacetylated K159/298R-C/EBP α mutant versus the hyperacetylated K159/298Q-C/EBP α mutant (Figure 6B), are seemingly contradictory to the results obtained with the naked (non-chromatinized) promoter-reporter assays. The reporter used in our study is activated by WT C/EBP α , and its activation is further increased by co-transfection of p300 (Figure 1D). The reporter is also strongly activated by the transfection of hyperacetylated



(A) HEK293T cells transfected with C/EBP α alone, C/EBP α with p300-HA, or C/EBP α with SIRT1-FLAG expression vectors. Immunohistochemistry was performed using anti-C/EBP α , anti-HA, and anti-FLAG antibodies. DNA was stained with DAPI to visualize the nucleus. Scale bars, 10 μ m. See Figure S2A for acetylation status of C/EBP α .

(C and D) HEK293T cells were transiently transfected with C/EBP-responsive luciferase reporter, *Renilla* expression vector for normalization, WT C/EBP α , or either (C) lysine-to-glutamine (KQ) or (D) lysine-to-arginine (KR) mutated C/EBP α expression vectors. Luciferase activity was measured 48 hr later (n = 3). Statistical differences were analyzed using Student's t tests. Error bars represent ±SD. **p < 0.01, ***p < 0.001; NS, not significant.


(E) HEK293T cells were transiently transfected with WT, K159/298Q, or K159/298R mutated C/EBP α -FLAG expression vectors. Immunohistochemistry was performed using anti-FLAG antibody. DNA was stained with DAPI to visualize the nucleus. Scale bars, 10 μ m.

(F) HEK293T cells were transiently transfected with WT, K159/298Q, or K159/298R mutated C/EBP α -FLAG expression vectors. C/EBP α proteins were purified by IP with anti-FLAG M2 beads. EMSA was performed using a double-stranded oligonucleotides containing either WT or mutated (mt) C/EBP α binding site.

(G) Fold enrichment of C/EBP-binding site DNA used in the C/EBP-responsive firefly reporter by DNA IP with WT, K159/298Q-, or K159/298R-C/EBP α -FLAG, using mouse anti-FLAG antibody versus non-specific mouse IgG. The experiment was performed in HEK293T cells, analyzed by real-time qPCR. Mean \pm SD (n = 3).

(H) Fold enrichment of DNA from endogenous C/EBP α target genes G-CSFR and PEPCK1 obtained by chromatin immunoprecipitation (ChIP) with WT, K159/298Q-, or K159/298R-C/EBP α -FLAG, using mouse anti-FLAG antibody versus non-specific mouse IgG. The experiment was performed in HEK293T cells, analyzed by real-time qPCR. Mean \pm SD (n = 3).

⁽B) HEK293T cells transfected with C/EBP α -FLAG alone, C/EBP α -FLAG with p300-HA, or C/EBP α -FLAG with SIRT1 expression vectors. C/EBP α -FLAG protein was purified by IP with anti-FLAG M2 beads. EMSA was performed using a double-stranded oligonucleotides containing either WT or mutated (mt) C/EBP α binding site.



K298Q-C/EBPa (Figures 4C and 4D) or K159/298Q-C/EBPa mutants (Figures 5B and 5D), while the effect of the hypoacetylated K298R- and K159/298R-C/EBPa mutants is similar to WT C/EBPa in the absence of p300 and inhibitory in the context of p300 co-transfection. This suggests that acetylation of C/EBPa increases its transcriptional activity, but it also shows that hypoacetylated K298R- and K159/298R-C/EBPa mutants still have a transactivation potential that is similar to WT C/EBPa in the absence of p300. Promoter-reporters have the limitation that the readout is determined by a selected naked DNA fragment; in our case it solely contains two natural C/EBP-binding sites of the cMGF promoter (Sterneck et al., 1992). Therefore, they cannot fully substitute for the more complex regulation of endogenous transcription that is influenced by chromatin modifiers and by other transcription factors that bind at the promoter and enhancer regions. Although we do not know whether the observed changes in the transcriptome are a result of direct promoter regulation through C/EBPa or of an indirect effect, the presence of C/EBP-binding sites in most of the genes speaks in favor of direct regulation (Table S3). Thus, the acetylation state of C/EBPa might discriminate between interaction partners and/or co-factors and thereby affect different endogenous promoters in opposite ways. The finding that upregulated genes in cells expressing the hyperacetylation K159/298Q-C/EBPa mutant fall into different GO categories compared with those induced by the hypoacetylation K159/298R-C/EBPa mutant supports such a scenario.

Figure 5. Acetylation of Lysine 298 of C/EBP α Stimulates Acetylation of Subsequent Lysines

(A) Immunoblot analysis of immunoprecipitated (IP) C/EBP α and total lysates (Input) of HEK293T cells ectopically expressing WT or one of the KR-C/EBP α mutants C/EBP α and p300-HA. Antibody staining as indicated.

(B) HEK293T cells were transiently transfected with luciferase C/EBP-responsive firefly reporter, *Renilla* expression vector for normalization, p300-HA, and either WT or one of the KR-C/EBP α mutant expression vectors. Luciferase activity was measured 48 hr later (n = 3).

(C) Immunoblot analysis of immunoprecipitated (IP) C/EBP α and total lysates (Input) of HEK293T cells ectopically expressing WT or one of the KQ-C/EBP α mutants C/EBP α and p300-HA. Antibody staining as indicated.


(D) HEK293T cells were transiently transfected with luciferase C/EBP-responsive firefly reporter, *Renilla* expression vector for normalization, p300-HA, and either WT or one of the KR-C/EBP α mutant expression vectors. Luciferase activity was measured after 48 hr (n = 3).

Statistical differences were analyzed using Student's t tests. Error bars represent \pm SD. *p < 0.05, **p < 0.01, ***p < 0.001; NS, not significant. K6, K159, K250, K273, K275, K276, and K298.

The C/EBP α acetylation switch involving p300 and SIRT1 is reminiscent of the acetylation of C/EBP ϵ regulated

by these same factors (Bartels et al., 2015). C/EBP ε is expressed exclusively in myeloid cells, and acetylation of two lysines (K121 and K198) is indispensable for C/EBP ε -induced terminal neutrophil differentiation. C/EBP ε -K121 is homologous to K159 of C/EBP α , and both are subject to sumoylation, and C/EBP ε -K198 is homologs to K276, which we found acetylated in C/EBP α , further supporting the similarities in the acetylation of both proteins. In agreement with our results, p300-mediated acetylation of C/EBP ε enhances transactivation of a C/EBP-binding site containing M-CSFR-promoter reporter, and the acetylation status does not affect cellular localization of C/EBP ε . In contrast to our findings obtained with deacetylated C/EBP α , non-acetylated C/EBP ε mutations are shown to reduce DNA binding, but DNA binding of WT C/EBP ε upon co-transfection with p300 or SIRT1 was not investigated (Bartels et al., 2015).

It has been shown that C/EBP α expression is essential for mitochondrial biogenesis and proper expression of both nuclear and mitochondrial genome-encoded genes in brown fat (Carmona et al., 2002). Our study shows that this function of C/EBP α depends on the hypoacetylated state of C/EBP α , which is provided by the energy-sensing deacetylase SIRT1, suggesting that C/EBP α mediates effects of SIRT1 on mitochondrial function. This is corroborated by the finding that the reduction of glucose concentration can induce mitochondrial respiration in WT C/EBP α -expressing cells but not in cells expressing either the acetylation-mimicking K159/298Q-C/EBP α mutant or the hypoacetylated K159/298R-C/EBP α mutant; while K159/298R Α



D

Figure 6. C/EBPa Acetylation Status Determines the C/EBPa-Regulated Transcriptome


(A) Immunoblot analysis of C/EBPα-FLAG and total lysates (Input) of Hepa1–6 cells expressing WT, K159/298Q-, and K159/298R-C/EBPα-FLAG cumateinducible constructs or empty vector (E.V.) control. Antibody staining as indicated.


(B) Heatmap of 232 differentially expressed genes (DEGs) in cumate-induced Hepa1–6 cells expressing K159/298R-C/EBPα-FLAG compared with the cells expressing K159/298Q-C/EBPα-FLAG as measured by RNA sequencing (RNA-seq). Low expression is shown in cyan, and high expression is in yellow. False discovery rate [FDR] adjusted p value < 0.01, and the medians in the WT condition are located between the medians of K159/298Q and K159/298R. See Table S2 for a complete list of DEGs.


(C) Relative mRNA expression levels (qRT-PCR) of ten upregulated (left) and ten downregulated (right) genes in cumate-induced Hepa1–6 cells expressing K159/298R-C/EBP α -FLAG compared with the cells expressing K159/298Q-C/EBP α -FLAG (n = 3). Corresponding p values are depicted as determined using Student's t test. Error bars represent ±SD.


(D) Representative functional annotation clusters of upregulated and downregulated genes in the 232 DEGs (Davis analysis adjusted enrichment score > 1.3). See Table S2 for the list of clustered genes.


mutant has already increased mitochondrial respiration at highglucose concentrations compared with WT C/EBP α , the respiration stays at a low level in the K159/298Q mutant-expressing cells. SIRT1 is known to control mitochondrial biogenesis and gene expression by deacetylating the transcriptional coactivator PPAR γ coactivator 1-alpha (PGC1 α) (Houtkooper et al., 2012; Rodgers et al., 2005; Gerhart-Hines et al., 2007; Nemoto et al.,














F

2.5 mM Glucose






Figure 7. Hypoacetylated C/EBPa Enhances Mitochondrial Function

(A) Cumate-induced Hepa1–6 cells expressing WT, K159/298Q-, or K159/298R-C/EBPα-FLAG were cultured in either high-glucose (25 mM) or low-glucose (2.5 mM) glucose medium, and mitochondrial mass was measured using MitoTracker fluorescent dye.

(B) Hepa1–6 cells with C/EBPα-KD (shC/EBPα) or control cells (shCTRL) were treated overnight with either DMSO as solvent or SIRT1 activator II. Mitochondrial mass was measured using MitoTracker fluorescent dye. Immunoblots of C/EBPα and β-actin loading control are shown at the right.

(C, E, and G) Basal and maximal OCR and SRC in cumate-induced Hepa1–6 cells expressing WT, K159/298Q-, or K159/298R-C/EBPα-FLAG proteins and cultured in medium with 25 mM glucose (C), 2.5 mM glucose (E), or 2.5 mM glucose (G) and treated with the SIRT1 inhibitor Ex-527 (selisistat) 16 hr before the measurement.

(legend continued on next page)

2005). In addition, SIRT1 controls the acetylation and function of forkhead box O (FOXO) transcription factors, which are important regulators of lipid and glucose metabolism as well as of stress responses (Houtkooper et al., 2012; Brunet et al., 2004; Motta et al., 2004; van der Horst et al., 2004). SIRT1 regulates adiponectin gene expression through stimulation of a FOXO1-C/EBPa transcriptional complex (Qiao and Shao, 2006). Here, FOXO1 is thought to be the target and deacetylated by SIRT1, but deacetylation of C/EBP α was not investigated in this study. By using a hypoacetylation (K159/298R) mutant, we demonstrate that C/EBPa deacetylation alone is sufficient for stimulating mitochondrial function. Whether deacetylated C/EBPa induces PGC1a expression (eventually in collaboration with FOXO transcription factors), collaborates with PGC1 a in the activation of mitochondrial genes, or acts independently of PCG1a remains to be analyzed in future experiments.

Recently, Bararia et al. (2016) showed that C/EBPa is acetylated by the KAT GCN5 at lysines K298 and K302 in the DNAbinding domain and K326 in the leucine zipper dimerization domain by using in vitro acetylation of short C/EBPa peptides and confirmation by mass spectrometry and western blotting using specific antibodies raised against acetylated C/EBPa. In the latter study, acetylated C/EBPa was found to be enriched in human myeloid leukemia cell lines and primary acute myeloid leukemia (AML) samples, and the data show that C/EBPa acetylation results in impaired DNA binding and thus loss of transcriptional activity, resulting in inhibition of C/EBPa granulopoietic function. We did not observe effects on DNA binding per se between hypo- or hyperacetylated C/EBPa. These differences may be the result of the different mutations used and the different experimental systems, hematopoietic cells in the study of Bararia et al. (2016) versus HEK293T and liver Hepa1-6 cells in our study. Bararia et al. (2016) showed loss of DNA binding and transactivation activity using dual K298Q/K302Q or triple K298Q/K302Q/K326Q mutants, which all reside in the basic leucine-zipper (bZIP) DNA-binding domain. Importantly, they reported that single acetylation-mimicking mutants of one of the three lysines showed no effect on DNA binding and transactivation. In our mass spectrometry analysis, K298Q, K302Q, and K326Q were not covered. K298 is predicted to be acetylated by p300 and deacetylated by SIRT1 (Table S1) and was identified as a p300 acetylation site by using Ac-K298-specific antibodies. We did not include K302 and K326, because they are not predicted as targets for p300 or SIRT1 (Table S1). Here we examined the dual K159Q/K298Q mutation, of which K159 lies outside the bZIP domain. Because we also do not see any effect on DNA binding with co-transfection of p300 and rather a stimulation of reporter promoter activity, we believe that at least in the experimental systems we use, acetylation of C/EBPa does not alter DNA binding. Bararia et al. (2016) found that co-transfection of p300 and C/EBPa resulted in stimulation of a C/EBP-binding site reporter, while co-transfection with GCN5 repressed the reporter. Similar to these results and to

other studies (Erickson et al., 2001; Bararia et al., 2016), we also found that co-expression of p300 and C/EBP α stimulates a C/EBP-dependent promoter reporter, but in our system, GCN5 did not alter the reporter activation in a dose-dependent manner (although GCN5 binds C/EBP α). Possibly, in different cellular systems, acetylation of C/EBP α can occur at different lysine residues by different KATs with different outcomes on DNA binding and/or transactivation. Different KAT regulatory pathways, C/EBP α -interacting proteins, or other PTMs of C/EBP α might influence this process. Overall, our data are more in agreement with the effects of acetylation and deacety-lation of C/EBP ϵ by p300 and SIRT1 (Bartels et al., 2015), as discussed above.

C/EBP α is subject of extensive PTMs, including phosphorylation, methylation, sumoylation, and ubiquitination (Leutz et al., 2011; Nerlov, 2008). Sumoylation of C/EBP α at lysine residue K159 reduces C/EBP α transactivation of the albumin gene in fetal primary hepatocytes and abrogates the interaction with Brahma-Related Gene-1 (BRG1), resulting in reduced inhibitory effect on cell proliferation (Kim et al., 2002; Sato et al., 2006). Acetylation and sumoylation at K159 are obviously mutually exclusive, and prevention of sumoylation by acetylation could be involved in the observed higher transcriptional efficacy of the K159Q mutant measured with the C/EBP-binding site reporter. However, the K159R that similarly prevents sumoylation at this site shows no enhanced activity, suggesting that lysine acetylation modulates the transcriptional activity of C/EBP α through other mechanisms.

Taken together, our results suggest that C/EBP α acetylation depends on nutrient (glucose) availability and is negatively controlled by the class III KDAC SIRT1. Our observations that hypoacetylation-mimicking C/EBP α mutant-expressing cells show increased expression of mitochondrial genes, higher mitochondrial mass, and mitochondrial respiration suggest that C/EBP α is a critical downstream mediator of SIRT1 mitochondrial function.

EXPERIMENTAL PROCEDURES

DNA Constructs

The pcDNA3-based full-length (p42) rat C/EBPa and rat C/EBPa-FLAG have been described earlier (Müller et al., 2010); cloning details are available upon request. See Supplemental Experimental Procedures for other plasmids used.

Cell Culture, Transfection, and Immunofluorescence

All cells were cultured in DMEM plus 10% fetal calf serum (FCS) (Invitrogen) and penicillin/streptomycin at 5% CO₂ and 37°C. HEK293T cells were seeded at 2.5 × 10⁶ cell in 10 cm dishes and transfected the next day with 5 µg expression vectors using calcium phosphate. The immunofluorescence staining protocol was described previously (Müller et al., 2010). The primary antibodies used were anti-C/EBP α (14AA; Santa Cruz Biotechnology), anti-FLAG (M2, F3165; Sigma-Aldrich), and anti-HA (MMS-101R; Convace). Secondary antibodies used were Alexa Fluor 488 or 568 conjugated (Invitrogen). p300 inhibitor C646 (CAS 328968-36-1; Sigma-Aldrich) was used at final concentration of 10 µM.

⁽D and F) Basal and maximal ECAR in cumate-induced Hepa1–6 cells expressing WT, K159/298Q-, or K159/298R-C/EBPα-FLAG proteins and cultured in medium with 25 mM (D) or 2.5 mM (F) glucose.

For all experiments (n = 5), statistical differences were analyzed using Student's t tests. Error bars represent ± SD. *p < 0.05, **p < 0.01, ***p < 0.001; NS, not significant.

ColP

CoIP was performed as described previously (Müller et al., 2010). Anti-C/EBP α (14AA; Santa Cruz Biotechnology), anti-FLAG (M2, F3165; Sigma-Aldrich), anti-HA (MMS-101R; Convace), and anti-Tip60 (NBP2-20647; Novus Biologicals) were used for precipitation as indicated. To detect the acetylation of C/EBP α in Fao cells, endogenous level, or in transiently transfected HEK293T cells, the cells were treated with the deacetylase inhibitors 1 μ M TSA (T8552; Sigma-Aldrich) and 5 mM NAM (47865U; Sigma-Aldrich) 8 hr before harvesting. The IP lysis buffer and IP wash buffer were supplemented with these inhibitors as well.

Immunoblotting

Western blotting was performed following a general protocol. The following antibodies were used: anti-C/EBP α (14AA), anti-SIRT1 (H-300), anti- α -tubulin (TU-02), anti-p300 (C-20), and anti-P/CAF (H-369) (Santa Cruz Biotechnology); anti-acetyl-Lys (05-515, clone 4G12; Millipore); anti-FLAG (M2, F3165; Sigma-Aldrich); anti-HA (MMS-101R; Convace), anti- β -actin (clone C4, 691001; MP Biomedicals), anti-Tip60 (NBP2-20647; Novus Biologicals), and anti-Ac-K298-C/EBP α (Bararia et al., 2016). Horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Amersham Life Technologies. The bands were visualized by chemiluminescence (ECL; Amersham Life Technologies).

Luciferase Assay

The luciferase construct containing two consensus C/EBP α -binding sites (pM82; lacking the AP-1-binding site) was described previously (Sterneck et al., 1992). For the luciferase assay, 25,000 HEK293T cells per well were seeded in 96-well plates. After 24 hr, cells were cotransfected with the luciferase reporter, *Renilla* expression vector, and other expression vectors as indicated using FuGENE HD (Promega). After 48 hr, luciferase activity was measured by Dual-Glo Luciferase Assay System (2920; Promega) (Promega).

In Vitro Deacetylation

In vitro deacetylation assay was performed as previously described (Li et al., 2008). Acetylated C/EBP α was obtained by co-transfecting HEK293T cells with C/EBP α -FLAG and p300 expression plasmids. Cells were treated with 10 μ M TSA and 5 mM NAM 8 hr before harvest. Anti-FLAG M2 beads (M8823; Sigma-Aldrich) were used for precipitation, and 3X-FLAG peptide (F4799; Sigma-Aldrich) was used for elution.

Lentiviral Transduction and Cumate-Inducible System

Hepa1–6 cells were infected with SparQ All-in-One Cumate Switch Vector (QM812B-1; System Bioscience) containing WT rC/EBP α -FLAG cDNA, K159/298Q-rC/EBP α -FLAG cDNA, K159/298R-rC/EBP α -FLAG cDNA, or empty vector and propagated under puromycin selection (1.5 µg/mL). Cumate-inducing solution was added to the cells at a dilution (1:1,000) 3 days before any experiment. To obtain the C/EBP α -knockdown (KD) Hepa1–6 cells, the cells were infected with pLKO.1 lentiviral constructs containing shRNAs against mouse C/EBP α : sh:5'-CCG GCA ACG CAA CGT GGA GAC GCA ACT CGA GTT GCG TCT CCA CGT TGC GTT GTT TTT-3' or non-target shRNA control (Sigma-Aldrich) and propagated under puromycin selection (1.5 µg/mL).

EMSA

HEK293T cells were transfected with expression vectors using the calcium phosphate method. Anti-FLAG M2 beads (M8823; Sigma-Aldrich) were used for precipitating C/EBP α -FLAG, and 3X-FLAG peptide (F4799; Sigma-Aldrich) was used for elution. Purified C/EBP α -FLAG was incubated with double-strand oligodeoxynucleotides containing either C/EBP consensus binding site or mutated one. The sense and antisense sequences are as follows: C/EBP consensus: sense 5'-CTA GCA TCT GCA GAT TGC GCA ATC TGC AC-3'; antisense 5'-TCG AGT GCA GAT TGC GCA ATC TGC AGA TG-3'; mutant C/EBP consensus: sense 5'-CTA GCA TCT GCA GAG GTA TAC CTC GCA CA-3'; antisense 5'-TCG AGT GCA GAT GCA GAG GTA TAC TGC GCA ATC TGC AGA TG-3'. The C/EBP consensus and mutant sequences are underlined.

C/EBP α DNA-binding affinity was analyzed using EMSA (EMSA) kit, with SYBR Green and SYPRO Ruby EMSA stain (E33075; Thermo Fisher Scientific), following the manufacturer's protocol.

Measurement of OCR

OCRs and ECARs were determined using a Seahorse XF96 Extracellular Flux analyzer (Seahorse Bioscience). Cumate-induced Hepa1–6 cells $(2.5 \times 10^4$ per well) were seeded into a 96-well XF cell culture microplate 24 hr prior to the assay (Supplemental Experimental Procedures).

Mass Spectrometry Analysis

HEK293T cells were transiently transfected with C/EBP α and p300-HA expression vectors. C/EBP α was immunoprecipitated using rabbit anti-C/EBP α antibody followed by SDS-PAGE and the proper C/EBP α protein band cut and used for further mass spectrometry (MS) protocol (Supplemental Experimental Procedures).

RNA Sequencing Analysis

Transcriptome analysis was done in triplicates. Hepa1–6 cells treated for 3 days with cumate solution to express WT, K159/298Q-, and K159/298R-C/ EBP α proteins were harvested, and the total RNAs were isolated using RNeasy Plus Mini Kit (74136; QIAGEN) according to the manufacturer's protocol (Supplemental Experimental Procedures).

Real-Time qPCR Analysis

Total RNA was isolated using the RNeasy Kit (QIAGEN). For cDNA synthesis, 1 µg RNA was reverse-transcribed with the Transcriptor First Strand cDNA Synthesis Kit (Roche) using Oligo(d)T primers. qRT-PCR was performed using the LightCycler 480 SYBR Green I Master Mix (Roche). Primer pairs are listed in Table S3.

Chromatin and Reporter C/EBP-Binding Site IP

HEK293T cells were transfected with WT, K159/298Q-, or K159/298R-C/EBP α expression vectors for the ChIP. HEK293T cells were cotransfected with C/EBP-binding site reporter construct and WT, K159/298Q-, or K159/298R-C/EBP α -FLAG expression vectors for the C/EBP-binding site IP. ChIP assay was performed with 5 \times 10⁶ cells using a Bioruptor (Diagenode) for sonication (details are available on request). ChIP antibodies were against FLAG (M2, F3165; Sigma-Aldrich) and non-specific mouse IgG (Santa Cruz Biotechnology). The fold enrichment was calculated relative to the background detected with non-specific rabbit IgG. For the semi-quantitative PCR, 1/50 (1 μ) of DNA obtained from the ChIP assay was used as template in a PCR with 28 cycles. Primer pairs are listed in Table S3.

Mitochondrial Content and mtDNA Copy Number

Mitochondrial mass was measured using the MitoTracker Red 480 kit following the manufacturer's protocol (M22425; Thermo Fisher Scientific). Fluorescence was measured using a GloMax-Multi Detection System (Promega). SIRT1 activator II (CAS 374922-43-7; 566313; Merck) was used at final concentration of 10 μ M. MtDNA was co-purified with genomic DNA from Hepa1–6 cells using standard protocol, Ct values were determined for cytochrome b gene encoded by mtDNA and β -actin gene encoded by the nuclear DNA, and the relative mtDNA copy number was calculated by normalizing to β -actin gene copy number. Primer pairs are listed in Table S3.

Mice

C57BL/6 male mice were housed individually with a standard 12-hr light/dark cycle at 22°C in a pathogen-free animal facility and were used for all experiments. Numbers of mice used in the separate experiments are given in the figure legends. Single caged mice 3 months of age were fed *ad libitum* or fed calorie restricted (70% of normal food intake) for 4 weeks. For the other experiment, mice were fed a HFD or normal control diet (Research Diets; product D12492: 60% fat, 20% carbohydrates, 20% protein; control diet D12450B: 10% fat, 70% carbohydrates, 20% protein) for 20 weeks. Mice were sacrificed by isoflurane at the end of each study. All animal experiments were performed in compliance with protocols approved by the Institutional Animal Care and Use Committee.

Statistics

Data were analyzed using two-tailed independent-samples Student's t tests for comparisons between two different groups and are expressed as mean \pm SD. The data met the assumptions of this test. Differences were considered to be significant when p < 0.05. The RNA-seq Analysis section in Supplemental Experimental Procedures contains details of statistical methods. No statistical methods were used to determine sample size, and randomization was not used for analyses.

DATA AND SOFTWARE AVAILABILITY

The accession number for the transcriptome RNA sequencing data reported in this paper is ArrayExpress: E-MTAB-6323.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, four figures, and three tables and can be found with this article online at https://doi.org/10.1016/j.celrep.2017.12.061.

ACKNOWLEDGMENTS

We thank Daniel Tenen, SCI Singapore/Harvard Medical School, for providing the anti-Ac-K298-C/EBP α antibody; Tony Kouzarides, Cambridge University, for providing the P/CAF-FLAG expression vector; Junjie Chen, University of Texas, for providing the Tip60 expression vector; and Richard Eckner, University of Zurich, for providing the p300-HA and Δ KAT-p300-HA expression vectors. M.A.Z. and T.A. were supported by the Leibniz Graduate School on Aging and Age-Related Diseases (LGSA; http://www.leibniz-fli.de/ career-development/graduates/) and the University Medical Center Groningen (UMCG). G.H. was supported by the LGSA and Deutsche Krebshilfe e.V. through a grant (110193) to C.F.C.

AUTHOR CONTRIBUTIONS

Conceptualization, M.A.Z., C.M., and C.F.C.; Investigation, M.A.Z., C.M., T.A., G.K., K.-H.G., F.F., T.V.J., and V.G.; Resources, O.H.K. and G.H.; Data Curation, M.A.Z., T.V.J., and V.G.; Writing – Original Draft, M.A.Z., C.M., and C.F.C.; Writing – Review & Editing, M.A.Z., C.M., and C.F.C.; Visualization, M.A.Z., T.V.J., and C.F.C.; Supervision, C.F.C.; Project Administration, C.F.C.; Funding Acquisition, M.A.Z. and C.F.C.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: June 28, 2017 Revised: October 26, 2017 Accepted: December 15, 2017 Published: January 9, 2018

REFERENCES

Bararia, D., Trivedi, A.K., Zada, A.A., Greif, P.A., Mulaw, M.A., Christopeit, M., Hiddemann, W., Bohlander, S.K., and Behre, G. (2008). Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP) as a co-activator of the myeloid transcription factor C/EBPalpha. Leukemia *22*, 800–807.

Bararia, D., Kwok, H.S., Welner, R.S., Numata, A., Sárosi, M.B., Yang, H., Wee, S., Tschuri, S., Ray, D., Weigert, O., et al. (2016). Acetylation of C/EBP α inhibits its granulopoietic function. Nat. Commun. 7, 10968.

Bartels, M., Govers, A.M., Fleskens, V., Lourenço, A.R., Pals, C.E., Vervoort, S.J., van Gent, R., Brenkman, A.B., Bierings, M.B., Ackerman, S.J., et al. (2015). Acetylation of C/EBP ε is a prerequisite for terminal neutrophil differentiation. Blood *125*, 1782–1792.

Brunet, A., Sweeney, L.B., Sturgill, J.F., Chua, K.F., Greer, P.L., Lin, Y., Tran, H., Ross, S.E., Mostoslavsky, R., Cohen, H.Y., et al. (2004). Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science *303*, 2011–2015.

Calkhoven, C.F., Müller, C., and Leutz, A. (2000). Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev. *14*, 1920–1932. Carmona, M.C., Iglesias, R., Obregón, M.J., Darlington, G.J., Villarroya, F., and Giralt, M. (2002). Mitochondrial biogenesis and thyroid status maturation in brown fat require CCAAT/enhancer-binding protein alpha. J. Biol. Chem.

277, 21489–21498. Choudhary, C., Weinert, B.T., Nishida, Y., Verdin, E., and Mann, M. (2014). The growing landscape of lysine acetylation links metabolism and cell signalling.

Nat. Rev. Mol. Cell Biol. 15, 536-550.

Croniger, C., Trus, M., Lysek-Stupp, K., Cohen, H., Liu, Y., Darlington, G.J., Poli, V., Hanson, R.W., and Reshef, L. (1997). Role of the isoforms of CCAAT/enhancer-binding protein in the initiation of phosphoenolpyruvate carboxykinase (GTP) gene transcription at birth. J. Biol. Chem. *272*, 26306– 26312.

Darlington, G.J., Wang, N., and Hanson, R.W. (1995). C/EBP alpha: a critical regulator of genes governing integrative metabolic processes. Curr. Opin. Genet. Dev. 5, 565–570.

Erickson, R.L., Hemati, N., Ross, S.E., and MacDougald, O.A. (2001). p300 coactivates the adipogenic transcription factor CCAAT/enhancer-binding protein alpha. J. Biol. Chem. *276*, 16348–16355.

Gerhart-Hines, Z., Rodgers, J.T., Bare, O., Lerin, C., Kim, S.H., Mostoslavsky, R., Alt, F.W., Wu, Z., and Puigserver, P. (2007). Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 26, 1913–1923.

Houtkooper, R.H., Pirinen, E., and Auwerx, J. (2012). Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. *13*, 225–238.

Huang, da W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57.

Inoue, Y., Inoue, J., Lambert, G., Yim, S.H., and Gonzalez, F.J. (2004). Disruption of hepatic C/EBPalpha results in impaired glucose tolerance and agedependent hepatosteatosis. J. Biol. Chem. 279, 44740–44748.

Jurado, L.A., Song, S., Roesler, W.J., and Park, E.A. (2002). Conserved amino acids within CCAAT enhancer-binding proteins (C/EBP(alpha) and beta) regulate phosphoenolpyruvate carboxykinase (PEPCK) gene expression. J. Biol. Chem. 277, 27606–27612.

Kim, J., Cantwell, C.A., Johnson, P.F., Pfarr, C.M., and Williams, S.C. (2002). Transcriptional activity of CCAAT/enhancer-binding proteins is controlled by a conserved inhibitory domain that is a target for sumoylation. J. Biol. Chem. 277, 38037–38044.

Lee, Y.H., Sauer, B., Johnson, P.F., and Gonzalez, F.J. (1997). Disruption of the c/ebp alpha gene in adult mouse liver. Mol. Cell. Biol. 17, 6014–6022.

Lefterova, M.I., Zhang, Y., Steger, D.J., Schupp, M., Schug, J., Cristancho, A., Feng, D., Zhuo, D., Stoeckert, C.J., Jr., Liu, X.S., and Lazar, M.A. (2008). PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev. *22*, 2941–2952.

Leutz, A., Pless, O., Lappe, M., Dittmar, G., and Kowenz-Leutz, E. (2011). Crosstalk between phosphorylation and multi-site arginine/lysine methylation in C/EBPs. Transcription *2*, 3–8.

Li, K., Casta, A., Wang, R., Lozada, E., Fan, W., Kane, S., Ge, Q., Gu, W., Orren, D., and Luo, J. (2008). Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation. J. Biol. Chem. *283*, 7590–7598.

Menzies, K.J., Zhang, H., Katsyuba, E., and Auwerx, J. (2016). Protein acetylation in metabolism - metabolites and cofactors. Nat. Rev. Endocrinol. *12*, 43–60.

Motta, M.C., Divecha, N., Lemieux, M., Kamel, C., Chen, D., Gu, W., Bultsma, Y., McBurney, M., and Guarente, L. (2004). Mammalian SIRT1 represses fork-head transcription factors. Cell *116*, 551–563.

Müller, C., Bremer, A., Schreiber, S., Eichwald, S., and Calkhoven, C.F. (2010). Nucleolar retention of a translational C/EBPalpha isoform stimulates rDNA transcription and cell size. EMBO J. *29*, 897–909.

Nemoto, S., Fergusson, M.M., and Finkel, T. (2005). SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1alpha. J. Biol. Chem. *280*, 16456–16460.

Nerlov, C. (2008). C/EBPs: recipients of extracellular signals through proteome modulation. Curr. Opin. Cell Biol. 20, 180–185.

Nishida, Y., Rardin, M.J., Carrico, C., He, W., Sahu, A.K., Gut, P., Najjar, R., Fitch, M., Hellerstein, M., Gibson, B.W., and Verdin, E. (2015). SIRT5 Regulates both Cytosolic and Mitochondrial Protein Malonylation with Glycolysis as a Major Target. Mol. Cell *59*, 321–332.

Park, J., Chen, Y., Tishkoff, D.X., Peng, C., Tan, M., Dai, L., Xie, Z., Zhang, Y., Zwaans, B.M., Skinner, M.E., et al. (2013). SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol. Cell *50*, 919–930.

Pedersen, T.A., Bereshchenko, O., Garcia-Silva, S., Ermakova, O., Kurz, E., Mandrup, S., Porse, B.T., and Nerlov, C. (2007). Distinct C/EBPalpha motifs regulate lipogenic and gluconeogenic gene expression in vivo. EMBO J. *26*, 1081–1093.

Qiao, L., and Shao, J. (2006). SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J. Biol. Chem. *281*, 39915–39924.

Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., and Puigserver, P. (2005). Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature *434*, 113–118.

Rosen, E.D., Hsu, C.H., Wang, X., Sakai, S., Freeman, M.W., Gonzalez, F.J., and Spiegelman, B.M. (2002). C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. *16*, 22–26.

Sato, Y., Miyake, K., Kaneoka, H., and lijima, S. (2006). Sumoylation of CCAAT/ enhancer-binding protein alpha and its functional roles in hepatocyte differentiation. J. Biol. Chem. *281*, 21629–21639. Shi, L., and Tu, B.P. (2015). Acetyl-CoA and the regulation of metabolism: mechanisms and consequences. Curr. Opin. Cell Biol. *33*, 125–131.

Siersbæk, R., and Mandrup, S. (2011). Transcriptional networks controlling adipocyte differentiation. Cold Spring Harb. Symp. Quant. Biol. 76, 247–255.

Sterneck, E., Müller, C., Katz, S., and Leutz, A. (1992). Autocrine growth induced by kinase type oncogenes in myeloid cells requires AP-1 and NF-M, a myeloid specific, C/EBP-like factor. EMBO J. *11*, 115–126.

van der Horst, A., Tertoolen, L.G., de Vries-Smits, L.M., Frye, R.A., Medema, R.H., and Burgering, B.M. (2004). FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J. Biol. Chem. 279, 28873–28879.

Verdin, E., and Ott, M. (2015). 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat. Rev. Mol. Cell Biol. *16*, 258–264.

Wang, N.D., Finegold, M.J., Bradley, A., Ou, C.N., Abdelsayed, S.V., Wilde, M.D., Taylor, L.R., Wilson, D.R., and Darlington, G.J. (1995). Impaired energy homeostasis in C/EBP alpha knockout mice. Science *269*, 1108–1112.

Wang, L., Du, Y., Lu, M., and Li, T. (2012). ASEB: a web server for KAT-specific acetylation site prediction. Nucleic Acids Res. 40, W376–W379.

Xiong, Y., and Guan, K.L. (2012). Mechanistic insights into the regulation of metabolic enzymes by acetylation. J. Cell Biol. *198*, 155–164.

Yang, J., Croniger, C.M., Lekstrom-Himes, J., Zhang, P., Fenyus, M., Tenen, D.G., Darlington, G.J., and Hanson, R.W. (2005). Metabolic response of mice to a postnatal ablation of CCAAT/enhancer-binding protein alpha. J. Biol. Chem. *280*, 38689–38699.

Yoshida, Y., Hughes, D.E., Rausa, F.M., 3rd, Kim, I.M., Tan, Y., Darlington, G.J., and Costa, R.H. (2006). C/EBPalpha and HNF6 protein complex formation stimulates HNF6-dependent transcription by CBP coactivator recruitment in HepG2 cells. Hepatology *43*, 276–286.